Literature DB >> 32010594

Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).

Wenhua Liang1,2, Kaican Cai3, Chun Chen4, Haiquan Chen5,6, Wentao Fang6, Junke Fu7, Xiangning Fu8, Shugeng Gao9, Jian Hu10, Yunchao Huang11, Ganning Jiang12, Wenjie Jiao13, Shanqing Li14, Gaofeng Li11, Hecheng Li15, Hui Li16, Xiaofei Li17, Naixin Liang14, Deruo Liu18, Hongxu Liu19, Jun Liu1,2, Lunxu Liu20, Yang Liu21, Qingquan Luo22, Haitao Ma23, Weimin Mao24, Zhongmin Peng25, Guibin Qiao26, Guoguang Shao27, Lijie Tan28, Qunyou Tan29, Qun Wang28, Changli Wang30, Qingchen Wu31, Shidong Xu32, Songtao Xu28, Lin Xu33, Yue Yang34, Fenglei Yu35, Baijiang Zhang36, Lanjun Zhang37, Bo Zhao8, Xiuyi Zhi38, Alessandro Brunelli39, René Horsleben Petersen40, Chia-Chuan Liu41, Biagio Ricciuti42, Giulio Metro42, Alessandro Tuzi43, Matteo B Suter43, Matthew Evison44, Nobuhiko Seki45, Shinji Sasada46, Takhiro Izumo47, William Chi-Shing Cho48, Jianxing He1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32010594      PMCID： PMC6976380          DOI： 10.21037/tlcr.2019.12.14

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  29 in total

1.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

2.  Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.

Authors:  Jacques Raphael; Mark Vincent; Gabriel Boldt; Prakesh S Shah; George Rodrigues; Phillip Blanchette
Journal:  Am J Clin Oncol       Date:  2019-05       Impact factor: 2.339

3.  Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

Authors:  Ning Li; Wei Ou; Xiong Ye; Hai-Bo Sun; Liang Zhang; Qin Fang; Song-Liang Zhang; Bao-Xiao Wang; Si-Yu Wang
Journal:  Ann Surg Oncol       Date:  2014-03-01       Impact factor: 5.344

4.  Development and Validation of Web-Based Nomograms to Precisely Predict Conditional Risk of Site-Specific Recurrence for Patients With Completely Resected Non-small Cell Lung Cancer: A Multiinstitutional Study.

Authors:  Yang Zhang; Difan Zheng; Juntao Xie; Yuan Li; Yiyang Wang; Chenguang Li; Jiaqing Xiang; Yawei Zhang; Hong Hu; Yihua Sun; Haiquan Chen
Journal:  Chest       Date:  2018-06-18       Impact factor: 9.410

5.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Authors:  Glenwood D Goss; Chris O'Callaghan; Ian Lorimer; Ming-Sound Tsao; Gregory A Masters; James Jett; Martin J Edelman; Rogerio Lilenbaum; Hak Choy; Fadlo Khuri; Katherine Pisters; David Gandara; Kemp Kernstine; Charles Butts; Jonathan Noble; Thomas A Hensing; Kendrith Rowland; Joan Schiller; Keyue Ding; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients.

Authors:  Hanyan Xu; Adam Abdul Hakeem Baidoo; Shanshan Su; Junru Ye; Chengshui Chen; Yupeng Xie; Luca Bertolaccini; Mahmoud Ismail; Biagio Ricciuti; Calvin Sze Hang Ng; Raja M Flores; Yuping Li
Journal:  Transl Lung Cancer Res       Date:  2019-04

8.  ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

Authors:  Yi-Long Wu; Roy S Herbst; Helen Mann; Yuri Rukazenkov; Marcelo Marotti; Masahiro Tsuboi
Journal:  Clin Lung Cancer       Date:  2018-05-01       Impact factor: 4.785

9.  K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.

Authors:  Y Fukuyama; T Mitsudomi; K Sugio; T Ishida; K Akazawa; K Sugimachi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321
View more
  12 in total

1.  Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC-opportunities and obstacles.

Authors:  Brielle A Parris; Steven Leong; Henry Marshall; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  Ann Transl Med       Date:  2021-04

2.  Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.

Authors:  Fengfeng Wang; Fei Meng; Sze Chuen Cesar Wong; William C S Cho; Sijun Yang; Lawrence W C Chan
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

3.  Implications of the success of EGFR-targeted therapy in advanced non-small cell lung cancer for its application to the adjuvant setting.

Authors:  Masayuki Takeda
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

4.  Adjuvant TKI treatment of EGFR-mutant lung cancer-already ripe for decision?

Authors:  Diego Kauffmann-Guerrero
Journal:  Transl Lung Cancer Res       Date:  2020-08

5.  Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer.

Authors:  Tatsuya Nagano; Motoko Tachihara; Daisuke Hazama; Yoshihiro Nishimura
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

6.  EGFR and non-small cell lung cancer: implications for surgical practice.

Authors:  Gonzalo Varela; Nuria M Novoa
Journal:  Ann Transl Med       Date:  2020-09

7.  One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer.

Authors:  Daniel Breadner; Jacques Raphael
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 3.005

8.  Postoperative management for non-small cell lung cancer harboring EGFR mutations.

Authors:  Fumihiro Tanaka; Kazue Yoneda; Masaru Takenaka
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

9.  Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all.

Authors:  Javeryah Safi; Sarah W Gordon; Peter Lee; Howard Li; Patrick Nana-Sinkam; Rachit D Shah; Ray W Shepherd; Samira Shojaee
Journal:  Ann Transl Med       Date:  2020-12

10.  EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.

Authors:  Joyce H S You; William C S Cho; Wai-Kit Ming; Yu-Chung Li; Chung-Kong Kwan; Kwok-Hung Au; Joseph Siu-Kie Au
Journal:  PLoS One       Date:  2021-03-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.